Ken Griffin Genprex, Inc. Transaction History

Citadel Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.19 - $0.37 $34,270 - $66,736	180,369 Added 1665.76%	191,197 $43,000
Q3 2023 Nov 14, 2023	BUY	$0.37 - $1.04 $4,006 - $11,261	10,828 New	10,828 $4,000
Q1 2023 May 15, 2023	SELL	$0.76 - $1.78 $17,028 - $39,882	-22,406 Reduced 62.78%	13,282 $12,000
Q4 2022 Feb 14, 2023	BUY	$1.0 - $58.8 $21,508 - $1.26 Million	21,508 Added 151.68%	35,688 $51,000
Q3 2022 Nov 14, 2022	BUY	$1.32 - $58.0 $18,717 - $822,440	14,180 New	14,180 $21,000
Q1 2022 May 16, 2022	BUY	$1.82 - $3.5 $33,659 - $64,729	18,494 Added 105.9%	35,958 $81,000
Q4 2021 Feb 14, 2022	SELL	$1.21 - $2.7 $9,454 - $21,097	-7,814 Reduced 30.91%	17,464 $22,000
Q3 2021 Nov 15, 2021	BUY	$2.59 - $3.36 $6,601 - $8,564	2,549 Added 11.21%	25,278 $67,000
Q3 2020 Nov 16, 2020	BUY	$2.9 - $4.29 $406 - $600	140 Added 0.62%	22,729 $76,000
Q2 2020 Aug 14, 2020	SELL	$1.99 - $3.64 $3,792 - $6,937	-1,906 Reduced 7.78%	22,589 $71,000
Q1 2020 May 15, 2020	SELL	$0.28 - $6.23 $1,969 - $43,821	-7,034 Reduced 22.31%	24,495 $59,000
Q2 2019 Aug 14, 2019	BUY	$1.2 - $1.85 $37,834 - $58,328	31,529 New	31,529 $39,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $76.8M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.